XML 53 R28.htm IDEA: XBRL DOCUMENT v3.19.3
Collaboration Agreements - Astellas Agreements - Additional Information (Detail) - USD ($)
$ in Thousands
1 Months Ended 9 Months Ended 12 Months Ended 35 Months Ended 45 Months Ended
Sep. 30, 2019
Apr. 30, 2006
Jun. 30, 2005
Sep. 30, 2019
Dec. 31, 2018
Feb. 28, 2009
Feb. 28, 2009
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Unbilled contract asset $ 180,000     $ 180,000 $ 0    
Europe [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Unbilled contract asset 130,000     130,000      
Astellas Agreement [Member] | Japan [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront, non-contingent and time-based payments received             $ 40,100
Potential milestone payments 12,500   $ 132,500        
Commercial sales milestone     15,000        
Aggregate consideration received 77,600     77,600      
Transaction price and allocated to performance obligations 12,500     12,500      
Astellas Agreement [Member] | Japan [Member] | Clinical and Development Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments     22,500        
Astellas Agreement [Member] | Japan [Member] | Regulatory Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments     $ 95,000        
Astellas Agreement [Member] | Europe [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront, non-contingent and time-based payments received           $ 320,000  
Potential milestone payments   $ 425,000          
Aggregate consideration received 410,000     410,000      
Transaction price and allocated to performance obligations 130,000     $ 130,000      
Percentage of joint development costs committed to fund   50.00%          
Additional consideration based on net sales description       low 20% range      
Estimated joint development extended service period         2023    
Revenue during period from performance obligations 129,000     $ 129,000      
Unbilled contract asset $ 130,000     $ 130,000      
Astellas Agreement [Member] | Europe [Member] | Clinical and Development Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments   $ 90,000          
Astellas Agreement [Member] | Europe [Member] | Regulatory Milestone [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Potential milestone payments   $ 335,000